{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:30:33Z","timestamp":1792740633724,"version":"4.5.0"},"reference-count":182,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019533","name":"Moderna Therapeutics Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019533","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.vaccine.2026.128394","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T19:24:20Z","timestamp":1771961060000},"page":"128394","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Evidence-based assessment of safety and mechanistic questions Related to mRNA COVID-19 Vaccines"],"prefix":"10.1016","volume":"77","author":[{"given":"Woo Yun","family":"Sohn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.G.","family":"Goody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darin K.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Urdaneta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian P.","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter L.","family":"Straus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bishoy","family":"Rizkalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.vaccine.2026.128394_bb0005","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2025.2223","article-title":"Global estimates of lives and life-years saved by COVID-19 vaccination during 2020-2024","volume":"6","author":"Ioannidis","year":"2025","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.vaccine.2026.128394_bb0010","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128394_bb0015","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.vaccine.2026.128394_bb0020","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 - preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"issue":"7830","key":"10.1016\/j.vaccine.2026.128394_bb0025","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"issue":"76","key":"10.1016\/j.vaccine.2026.128394_bb0030","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/cid\/ciac785","article-title":"Effectiveness of messenger RNA-1273 vaccine booster against coronavirus disease 2019 in immunocompetent adults","author":"Florea","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128394_bb0035","article-title":"Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: interim results from a prospective observational cohort study","volume":"6","author":"Bruxvoort","year":"2022","journal-title":"Lancet Reg Health Am"},{"key":"10.1016\/j.vaccine.2026.128394_bb0040","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1016\/j.vaccine.2023.06.016","article-title":"Effectiveness of a fourth dose of mRNA-1273 against COVID-19 among older adults in the United States: interim results from an observational cohort study","volume":"41","author":"Ku","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128394_bb0045","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/s41591-022-01753-y","article-title":"Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and Delta variants","volume":"28","author":"Tseng","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2026.128394_bb0050","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-41537-7","article-title":"mRNA-1273 bivalent (original and omicron) COVID-19 vaccine effectiveness against COVID-19 outcomes in the United States","volume":"14","author":"Tseng","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.128394_bb0055","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae695","article-title":"Effectiveness of the 2023\u20132024 omicron XBB.1.5-containing mRNA COVID-19 vaccine (mRNA-1273.815) in preventing COVID-19\u2013related hospitalizations and medical encounters among adults in the United States","volume":"11","author":"Kopel","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"24","key":"10.1016\/j.vaccine.2026.128394_bb0060","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1056\/NEJMc2114089","article-title":"Effectiveness of the mRNA-1273 vaccine during a SARS-CoV-2 Delta outbreak in a prison","volume":"385","author":"Chin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128394_bb0065","article-title":"Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study","volume":"374","author":"Chung","year":"2021","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128394_bb0070","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(25)00380-9","article-title":"Effectiveness of the BNT162b2 and mRNA-1273 JN.1-adapted vaccines against COVID-19-associated hospitalisation and death: a Danish, nationwide, register-based, cohort study","volume":"25","author":"Hansen","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128394_bb0075","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-072808","article-title":"Comparative effectiveness of BNT162b2 versus mRNA-1273 COVID-19 vaccine boosting in England: matched cohort study in OpenSAFELY-TPP","volume":"380","author":"Hulme","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2026.128394_bb0080","article-title":"Comparative COVID-19 vaccine effectiveness over time in veterans. Open forum","volume":"9","author":"Mayr","year":"2022","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.vaccine.2026.128394_bb0085","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41564-022-01272-z","article-title":"Comparative effectiveness of third doses of mRNA-based COVID-19 vaccines in US veterans","volume":"8","author":"Dickerman","year":"2023","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.vaccine.2026.128394_bb0090","article-title":"Relative effectiveness of BNT162b2, mRNA-1273, and Ad26.COV2.S vaccines and homologous boosting in preventing COVID-19 in adults in the US. Open forum","volume":"10","author":"Nguyen","year":"2023","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.vaccine.2026.128394_bb0095","article-title":"Comparative effectiveness of the bivalent (original\/omicron BA.4\/BA.5) mRNA COVID-19 vaccines mRNA-1273.222 and BNT162b2 bivalent in adults with underlying medical conditions in the United States","volume":"12","author":"Kopel","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128394_bb0100","article-title":"Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines in immunocompromised individuals: a systematic review and meta-analysis using the GRADE framework","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128394_bb0105","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s40121-024-00936-z","article-title":"Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines among older adults: systematic literature review and meta-analysis using the GRADE framework","volume":"13","author":"Kavondikala","year":"2024","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.vaccine.2026.128394_bb0110","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1007\/s12325-025-03117-7","article-title":"Comparative effectiveness of the mRNA-1273 and BNT162b2 COVID-19 vaccines among adults with underlying medical conditions: a systematic literature review and pairwise meta-analysis using GRADE","volume":"42","author":"Wang","year":"2025","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128394_bb0115","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2335052","article-title":"Effectiveness and durability of mRNA-1273 BA.4\/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4\/BA.5 and XBB sublineages","volume":"20","author":"Ackerson","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.128394_bb0120","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1080\/14760584.2024.2402955","article-title":"A descriptive review on the real-world impact of Moderna, Inc. COVID-19 vaccines","volume":"23","author":"Bausch-Jurken","year":"2024","journal-title":"Expert Rev Vaccines"},{"issue":"16","key":"10.1016\/j.vaccine.2026.128394_bb0125","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"COVID-19 vaccine effectiveness against the omicron variant","volume":"21","author":"Andrews","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128394_bb0130","doi-asserted-by":"crossref","first-page":"5456","DOI":"10.1016\/j.vaccine.2021.08.060","article-title":"Vaccine effectiveness against transmission of alpha, delta and omicron SARS-COV-2-infection, Belgian contact tracing, 2021-2022","volume":"39","author":"Braeye","year":"2021","journal-title":"Vaccine"},{"issue":"48","key":"10.1016\/j.vaccine.2026.128394_bb0135","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2023.28.48.2300173","volume":"28","author":"Chatzilena","year":"2023","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2026.128394_bb0140","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ijid.2023.01.040","article-title":"Effectiveness of a nationwide COVID-19 vaccination program in Mexico against symptomatic COVID-19, hospitalizations, and death: a retrospective analysis of national surveillance data","volume":"129","author":"Bello-Chavolla","year":"2023","journal-title":"Int J Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128394_bb0145","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.32760","article-title":"Effectiveness of COVID-19 Vaccines against omicron or Delta symptomatic infection and severe outcomes","volume":"5","author":"Buchan","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128394_bb0150","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.7326\/M21-1577","article-title":"SARS-CoV-2 vaccine effectiveness in a high-risk National Population in a real-world setting","volume":"174","author":"Butt","year":"2021","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128394_bb0155","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1093\/cid\/ciac328","article-title":"Relative vaccine effectiveness of a severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine booster dose against the omicron variant","volume":"75","author":"Butt","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128394_bb0160","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3201\/eid2803.212027","article-title":"Effectiveness of 3 COVID-19 Vaccines in preventing SARS-CoV-2 infections, January-May 2021, Aragon","volume":"28","author":"Del Cura-Bilbao","year":"2022","journal-title":"Spain Emerg Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128394_bb0165","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/cid\/ciac110","article-title":"Effectiveness of BNT162b2 and mRNA-1273 second doses and boosters for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and SARS-CoV-2-Related hospitalizations: a statewide report from the Minnesota electronic health record consortium","volume":"75","author":"Drawz","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128394_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003992","article-title":"Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the alpha, Delta, or omicron SARS-CoV-2 variant: a nationwide Danish cohort study","volume":"19","author":"Gram","year":"2022","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2026.128394_bb0175","article-title":"Effectiveness estimates of three COVID-19 vaccines based on observational data from Puerto Rico","volume":"9","author":"Robles-Font\u00e1n","year":"2022","journal-title":"Lancet Reg Health Am"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128394_bb0180","article-title":"COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes from Delta AY.4.2: cohort and test-negative study of 5.4 million individuals in Scotland","volume":"9","author":"Kerr","year":"2022","journal-title":"J Glob Health"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128394_bb0185","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1056\/NEJMoa2117128","article-title":"Effectiveness of Covid-19 Vaccines over a 9-month period in North Carolina","volume":"386","author":"Lin","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128394_bb0190","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S1473-3099(22)00146-3","article-title":"COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID study","volume":"22","author":"Menni","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128394_bb0195","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/S1473-3099(22)00292-4","article-title":"Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study","volume":"22","author":"Monge","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128394_bb0200","article-title":"Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: a nationwide cohort study","volume":"11","author":"Nordstr\u00f6m","year":"2021","journal-title":"Lancet Reg Health Eur"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128394_bb0205","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.medj.2021.06.007","article-title":"FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system","volume":"2","author":"Pawlowski","year":"2021","journal-title":"Med"},{"issue":"25","key":"10.1016\/j.vaccine.2026.128394_bb0210","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2106599","article-title":"Vaccine effectiveness among healthcare personnel study team. Effectiveness of mRNA Covid-19 vaccine among U.S. health care personnel","volume":"385","author":"Pilishvili","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128394_bb0215","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1093\/cid\/ciab687","article-title":"Effectiveness of severe acute respiratory syndrome coronavirus 2 messenger RNA Vaccines for preventing coronavirus disease 2019 hospitalizations in the United States","volume":"74","author":"Tenforde","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128394_bb0220","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.cmi.2021.11.011","article-title":"Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary-the HUN-VE study","volume":"28","author":"Vok\u00f3","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128394_bb0225","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40121-024-01091-1","article-title":"Evaluating the effectiveness of mRNA-1273.815 against COVID-19 hospitalization among adults aged\u226518 years in the United States","volume":"14","author":"Wilson","year":"2025","journal-title":"Infect Dis Ther"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128394_bb0230","article-title":"COVID-19 mRNA vaccination and 4-year all-cause mortality among adults aged 18\u201359 years in France","volume":"8","author":"Semenzato","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"14","key":"10.1016\/j.vaccine.2026.128394_bb0235","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jama.2021.15072","article-title":"Surveillance for adverse events after COVID-19 mRNA vaccination","volume":"326","author":"Klein","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2026.128394_bb0240","author":"U.S. Food and Drug Administration (FDA)"},{"key":"10.1016\/j.vaccine.2026.128394_bb0245","author":"Centers for Disease Control and Prevention (CDC)"},{"issue":"22","key":"10.1016\/j.vaccine.2026.128394_bb0250","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMsa2514268","article-title":"Updated evidence for COVID-19, RSV, and influenza vaccines for 2025\u20132026","volume":"393","author":"Scott","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128394_bb0255","article-title":"Safety monitoring of multiple health outcomes following 2023\u20132024 COVID-19 vaccination among Medicare beneficiaries aged 65 years and older in the United States","author":"Gruber","year":"2025","journal-title":"medRxiv [preprint]"},{"key":"10.1016\/j.vaccine.2026.128394_bb0260","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae067","article-title":"Global safety assessment of adverse events of special interest following 2 years of use and 772 million administered doses of mRNA-1273","volume":"11","author":"Urdaneta","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128394_bb0265","doi-asserted-by":"crossref","first-page":"e544","DOI":"10.1093\/cid\/ciac446","article-title":"Analysis of myocarditis among 252 million mRNA-1273 recipients worldwide","volume":"76","author":"Straus","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128394_bb0270","author":"ACIP meeting, 25\u201326 June 2025"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128394_bb0275","doi-asserted-by":"crossref","first-page":"6085","DOI":"10.1038\/s41467-024-49634-x","article-title":"COVID-19 National core study. Cohort study of cardiovascular safety of different COVID-19 vaccination doses among 46 million adults in England","volume":"15","author":"Ip","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128394_bb0280","doi-asserted-by":"crossref","DOI":"10.1136\/bmjph-2024-001859","article-title":"COVID-19 mRNA vaccination and all-cause mortality in the adult population in nation during 2021-2023: a population-based cohort study","volume":"4","author":"Dahl","year":"2026","journal-title":"BMJ Public Health"},{"key":"10.1016\/j.vaccine.2026.128394_bb0285","article-title":"Maternal and infant outcomes following exposure to SPIKEVAX during pregnancy: an observational database study. [Abstract 61]. ABSTRACTS of the 2024 ISPE annual meeting, Berlin, Germany","volume":"33","author":"Kalloo","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2026.128394_bb0290","series-title":"Presented at the International Society for Pharmacoepidemiology Annual Meeting","article-title":"Monitoring the safety of mRNA-1273 COVID-19 Vaccines in pregnancy: a multi-database study in Denmark, Norway, Spain and the United Kingdom. A regulator-mandated post-authorisation safety study in the VAC4EU network (EUPAS44450)","author":"Ehrenstein","year":"2025"},{"key":"10.1016\/j.vaccine.2026.128394_bb0295","series-title":"Presented at the International Society for Pharmacoepidemiology Annual Meeting","article-title":"Monitoring the safety of mRNA-1273 COVID-19 vaccine in the general population: results of a regulator-mandated post-authorisation safety study in Denmark, Norway, Spain, and the United Kingdom (EUPAS44273)","author":"S\u00f8rup","year":"2025"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128394_bb0300","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.53845","article-title":"Reports of Guillain\u2013Barr\u00e9 syndrome after COVID-19 vaccination in the United States","volume":"6","author":"Abara","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2026.128394_bb0305","author":"Advisory Committee on Immunization Practices (ACIP) meeting, April 2023"},{"key":"10.1016\/j.vaccine.2026.128394_bb0310","author":"Advisory Committee on Immunization Practices (ACIP) meeting, June 2024"},{"key":"10.1016\/j.vaccine.2026.128394_bb0315","article-title":"Signal detection, refinement, and evaluation of cerebral venous sinus thrombosis following mRNA-1273 administration","author":"Bush","year":"2023","journal-title":"Abstract Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2026.128394_bb0320","article-title":"Estimating the risk of transient ischemic attacks and non-hemorrhagic stroke following mRNA-1273 bivalent vaccination","author":"Bush","year":"2024","journal-title":"Abstract Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2026.128394_bb0325","author":"Centers for Disease Control and Prevention"},{"key":"10.1016\/j.vaccine.2026.128394_bb0330","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s40264-024-01458-w","article-title":"Safety and effectiveness of COVID-19 vaccines during pregnancy","volume":"47","author":"Ciapponi","year":"2024","journal-title":"Drug Saf"},{"key":"10.1016\/j.vaccine.2026.128394_bb0335","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-024-12186-7","article-title":"Guillain\u2013Barr\u00e9 syndrome and COVID-19 vaccination: systematic review and meta-analysis","author":"Censi","year":"2024","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128394_bb0340","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/infdis\/jiad051","article-title":"Surveillance for multisystem inflammatory syndrome in children after COVID-19 vaccination among children aged 5\u201311 years","volume":"228","author":"Cortese","year":"2023","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128394_bb0345","first-page":"285","article-title":"COVID-19 vaccination and stillbirth","volume":"144","author":"Denoble","year":"2024","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2026.128394_bb0350","article-title":"Evaluation of postmenopausal hemorrhage following Moderna COVID-19 vaccination","author":"Dharia","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128394_bb0355","doi-asserted-by":"crossref","first-page":"e591","DOI":"10.1093\/infdis\/jiae140","article-title":"Safety and immunogenicity of mRNA-1273 in solid organ transplant recipients","volume":"230","author":"Figueroa","year":"2024","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128394_bb0360","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2023-061894","article-title":"Safety of COVID-19 mRNA vaccination among young children","volume":"152","author":"Goddard","year":"2023","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2026.128394_bb0365","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41586-025-09655-y","article-title":"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade","volume":"647","author":"Grippin","year":"2025","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128394_bb0370","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2204399","article-title":"Maternal vaccination and risk of COVID-19 hospitalization in infants","volume":"387","author":"Halasa","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128394_bb0375","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2022-057313","article-title":"Safety of COVID-19 vaccination in children aged 5\u201311 years","author":"Hause","year":"2022","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2026.128394_bb0380","article-title":"COVID-19 mRNA vaccine safety among children aged 6 months\u20135 years","author":"Hause","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2026.128394_bb0385","article-title":"Safety monitoring of bivalent COVID-19 booster vaccination among children aged 5\u201311 years","author":"Hause","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128394_bb0390","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2022-060295","article-title":"COVID-19 vaccine safety in adolescents","volume":"151","author":"Hesse","year":"2023","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128394_bb0395","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.8192","article-title":"Safety of ancestral monovalent BNT162b2, mRNA-1273, and NVX-CoV2373 COVID-19 Vaccines in US children aged 6 months to 17 years","volume":"7","author":"Hu","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128394_bb0400","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/ene.15147","article-title":"Neurological autoimmune diseases following SARS-CoV-2 vaccination","volume":"29","author":"Kaulen","year":"2022","journal-title":"Eur J Neurol"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128394_bb0405","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1001\/jamapediatrics.2024.1917","article-title":"COVID-19 vaccination in the first trimester and major structural birth defects among live births","volume":"178","author":"Kharbanda","year":"2024","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.vaccine.2026.128394_bb0410","doi-asserted-by":"crossref","DOI":"10.1038\/d41586-025-03432-7","article-title":"People with some cancers live longer after a COVID vaccine","author":"Kozlov","year":"2025","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128394_bb0415","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S2352-4642(22)00244-9","article-title":"Outcomes at least 90 days since onset of myocarditis after mRNA COVID-19 vaccination in adolescents and young adults in the USA: a follow-up surveillance study","volume":"6","author":"Kracalik","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"issue":"379","key":"10.1016\/j.vaccine.2026.128394_bb0420","article-title":"Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid-19 vaccines: international network cohort study from five European countries and the US","volume":"26","author":"Li","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2026.128394_bb0425","article-title":"COVID-19 vaccination during pregnancy and birth outcomes","author":"Lipkind","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128394_bb0430","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1001\/jama.2024.1059","article-title":"Stroke risk after COVID-19 bivalent vaccination among US older adults","volume":"331","author":"Lu","year":"2024","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128394_bb0435","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.7149","article-title":"Severe maternal morbidity and mortality of pregnant patients with COVID-19 infection during the early pandemic period in the US","volume":"6","author":"Matsuo","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2026.128394_bb0440","series-title":"Evidence Review of the Adverse Effects of COVID-19 Vaccination","author":"National Academies of sSciences, eEngineering, and mMedicine","year":"2024"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128394_bb0445","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1001\/jama.2023.26945","article-title":"Neonatal outcomes after COVID-19 vaccination in pregnancy","volume":"331","author":"Norman","year":"2024","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128394_bb0450","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128394_bb0455","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1038\/s41591-021-01556-7","article-title":"Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection","volume":"27","author":"Patone","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2026.128394_bb0460","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.eclinm.2023.102154","article-title":"Risk of autoimmune diseases following COVID-19 and the potential protective effect from vaccination: a population-based cohort study","volume":"63","author":"Peng","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.vaccine.2026.128394_bb0465","article-title":"Safety of Moderna\u2019s mRNA-1273.222 bivalent Omicron-containing vaccine: interim results from a US claims database cohort study. Abstract 501","author":"Rahai","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128394_bb0470","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/humrep\/dead036","article-title":"The risk of miscarriage following COVID-19 vaccination: a systematic review and meta-analysis","volume":"38","author":"Rimmer","year":"2023","journal-title":"Hum Reprod"},{"key":"10.1016\/j.vaccine.2026.128394_bb0475","author":"Safety Platform for Emergency Vaccines"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128394_bb0480","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1001\/jamapediatrics.2021.1050","article-title":"Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: the INTERCOVID multinational cohort study","volume":"175","author":"Villar","year":"2021","journal-title":"JAMA Pediatr"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128394_bb0485","article-title":"Myocarditis in SARS-CoV-2 infection vs. COVID-19 vaccination: a systematic review and meta-analysis","volume":"29","author":"Voleti","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"16","key":"10.1016\/j.vaccine.2026.128394_bb0490","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1001\/jama.2021.16496","article-title":"Association of Receipt of the Ad26.COV2.S COVID-19 vaccine with presumptive Guillain-Barr\u00e9 syndrome, February-July 2021","volume":"326","author":"Woo","year":"2021","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128394_bb0495","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1056\/NEJMoa2403211","article-title":"Postacute sequelae of SARS-CoV-2 infection in the Pre-Delta, Delta, and omicron eras","volume":"391","author":"Xie","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128394_bb0500","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.vaccine.2022.12.026","article-title":"A broad assessment of covid-19 vaccine safety using tree-based data-mining in the vaccine safety datalink","volume":"41","author":"Yih","year":"2023","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128394_bb0505","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S2352-4642(22)00028-1","article-title":"Reported cases of multisystem inflammatory syndrome in children aged 12\u201320 years in the USA who received a COVID-19 vaccine, December, 2020, through August, 2021: a surveillance investigation","volume":"6","author":"Yousaf","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.vaccine.2026.128394_bb0510","author":"World Health Organization (WHO)"},{"key":"10.1016\/j.vaccine.2026.128394_bb0515","article-title":"WHO health emergencies Programme COVID-19 infection prevention and control guideline development group. Summary of WHO infection prevention and control guideline for COVID-19: striving for evidence-based practice in infection prevention and control","volume":"385","author":"Dunn","year":"2024","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128394_bb0520","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2026.128394_bb0525","author":"NIH Decades in the Making: mNRA COVID-19 vaccines"},{"issue":"18","key":"10.1016\/j.vaccine.2026.128394_bb0530","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1056\/NEJMp2027405","article-title":"Developing safe and effective Covid Vaccines - operation warp speed\u2019s strategy and approach","volume":"383","author":"Slaoui","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128394_bb0535","author":"Good manufacturing practice. European Medicines Agency (EMA)"},{"key":"10.1016\/j.vaccine.2026.128394_bb0540","author":"Center for Drug Evaluation and Research"},{"key":"10.1016\/j.vaccine.2026.128394_bb0550","author":"International Council for Harmonisation (ICH)"},{"key":"10.1016\/j.vaccine.2026.128394_bb0555","author":"International Council for Harmonisation (ICH)"},{"key":"10.1016\/j.vaccine.2026.128394_bb0560","author":"International Council for Harmonisation (ICH)"},{"key":"10.1016\/j.vaccine.2026.128394_bb0565","author":"International Council for Harmonisation (ICH)"},{"key":"10.1016\/j.vaccine.2026.128394_bb0570","author":"International Council for Harmonisation (ICH)"},{"key":"10.1016\/j.vaccine.2026.128394_bb0575","series-title":"Working Group presentation: safety uncertainties of mRNA COVID-19 vaccines","author":"Advisory Committee on Immunization Practices (ACIP)","year":"2025"},{"key":"10.1016\/j.vaccine.2026.128394_bb0580","author":"Advisory Committee on Immunization Practices (ACIP)"},{"key":"10.1016\/j.vaccine.2026.128394_bb0590","author":"European Medicines Agency (EMA) Safety of COVID-19 vaccines"},{"key":"10.1016\/j.vaccine.2026.128394_bb0595","author":"COVID-19 Immunity task force"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128394_bb0600","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-051254","article-title":"The Canadian National Vaccine Safety Network: surveillance of adverse events following immunisation among individuals immunised with the COVID-19 vaccine, a cohort study in Canada","volume":"12","author":"Bettinger","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2026.128394_bb0605","author":"AusVaxSafety"},{"key":"10.1016\/j.vaccine.2026.128394_bb0610","author":"Therapeutic Goods Administration"},{"key":"10.1016\/j.vaccine.2026.128394_bb0615","author":"Vaccines and Related Biological Products Advisory Committee (VRBPAC)"},{"key":"10.1016\/j.vaccine.2026.128394_bb0620","unstructured":"Data On Filfe: Number of mNEXSPIKE distributed."},{"key":"10.1016\/j.vaccine.2026.128394_bb0625","author":"mNEXSPIKE (COVID-19 Vaccine, mRNA). 2025\u20132026 formula prescribing information"},{"key":"10.1016\/j.vaccine.2026.128394_bb0630","unstructured":"Moderna Data on File. List of SPIKEVAX approvals."},{"key":"10.1016\/j.vaccine.2026.128394_bb0635","author":"Pfizer press release"},{"key":"10.1016\/j.vaccine.2026.128394_bb0640","author":"U.S. Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER)"},{"key":"10.1016\/j.vaccine.2026.128394_bb0645","author":"European Medicines Agency"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128394_bb0650","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S1473-3099(23)00295-5","article-title":"Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial","volume":"23","author":"Lee","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128394_bb0655","doi-asserted-by":"crossref","first-page":"7469","DOI":"10.1038\/s41467-024-50376-z","article-title":"Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases","volume":"15","author":"Baden","year":"2024","journal-title":"Nat Commun"},{"issue":"24","key":"10.1016\/j.vaccine.2026.128394_bb0660","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1056\/NEJMoa2109522","article-title":"Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents","volume":"385","author":"Ali","year":"2021","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.vaccine.2026.128394_bb0665","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa2203315","article-title":"Evaluation of mRNA-1273 Covid-19 vaccine in children 6 to 11 years of age","volume":"386","author":"Creech","year":"2022","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.vaccine.2026.128394_bb0670","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa2209367","article-title":"Evaluation of mRNA-1273 vaccine in children 6 months to 5 years of age","volume":"387","author":"Anderson","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128394_bb0675","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.jaad.2024.10.063","article-title":"COVID-19 infection is associated with an elevated risk for autoimmune blistering diseases while COVID-19 vaccination decreases the risk: a large-scale population-based cohort study of 112 million individuals","volume":"92","author":"Curman","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128394_bb0680","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.14309\/ajg.0000000000001342","article-title":"Adverse events after SARS-CoV-2 mRNA vaccination among patients with inflammatory bowel disease","volume":"116","author":"Botwin","year":"2021","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128394_bb0685","first-page":"9","article-title":"COVID-19 vaccination reactogenicity in persons with multiple sclerosis","volume":"9","author":"FBS","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128394_bb0690","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/art.41937","article-title":"Evaluation of immune response and disease status in systemic lupus erythematosus patients following SARS-CoV-2 vaccination","volume":"74","author":"Izmirly","year":"2022","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128394_bb0695","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/ene.15602","article-title":"Neurological autoimmune diseases following vaccinations against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a follow-up study","volume":"30","author":"Doubrovinskaia","year":"2023","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.vaccine.2026.128394_bb0700","author":"Therapeutic Goods Administration (TGA)"},{"issue":"16","key":"10.1016\/j.vaccine.2026.128394_bb0705","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.vaccine.2021.03.038","article-title":"mRNA vaccines manufacturing: challenges and bottlenecks","volume":"39","author":"Rosa","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128394_bb0710","author":"U.S. Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER)"},{"key":"10.1016\/j.vaccine.2026.128394_bb0715","series-title":"Guidelines on the quality, safety and efficacy of biotherapeutic protein products prepared by recombinant DNA technology","volume":"No. 987","author":"World Health Organization (WHO)","year":"2014"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128394_bb0720","doi-asserted-by":"crossref","DOI":"10.1080\/08916934.2025.2551517","article-title":"Quantification of residual plasmid DNA and SV40 promoter-enhancer sequences in Pfizer\/BioNTech and Moderna modRNA COVID-19 vaccines from Ontario, Canada","volume":"58","author":"Speicher","year":"2025","journal-title":"Autoimmunity"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128394_bb0725","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/mps7030041","article-title":"Methodological considerations regarding the quantification of DNA impurities in the COVID-19 mRNA vaccine Comirnaty\u00ae","volume":"7","author":"K\u00f6nig","year":"2024","journal-title":"Methods Protoc"},{"key":"10.1016\/j.vaccine.2026.128394_bb0730","article-title":"BioNTech RNA-based COVID-19 injections contain large amounts of residual DNA including an SV40 promoter\/enhancer sequence","volume":"5","author":"K\u00e4mmerer","year":"2024","journal-title":"Sci Public Health Policy Law"},{"key":"10.1016\/j.vaccine.2026.128394_bb0735","series-title":"Confirmation of the presence of vaccine DNA in the Pfizer anti-COVID-19 vaccine","author":"Raoult","year":"2024"},{"issue":"55","key":"10.1016\/j.vaccine.2026.128394_bb0740","article-title":"Quantification of objective concentrations of DNA impurities in mRNA vaccines","volume":"10","author":"Kaiser","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128394_bb0745","author":"Paul-Ehrlich-Institut (PEI)"},{"issue":"56","key":"10.1016\/j.vaccine.2026.128394_bb0750","article-title":"Opting for the appropriate methodology for quantification of residual DNA impurities in mRNA vaccines","volume":"22","author":"Vieths","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128394_bb0755","author":"Therapeutic Goods Administration (TGA)"},{"key":"10.1016\/j.vaccine.2026.128394_bb0760","series-title":"ICH Harmonised Guideline S12: Nonclinical biodistribution considerations for gene therapy products","author":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)","year":"2023"},{"key":"10.1016\/j.vaccine.2026.128394_bb0765","author":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)"},{"key":"10.1016\/j.vaccine.2026.128394_bb0770","series-title":"ICH harmonised guideline E19: optimisation of safety data collection","author":"International Council for Harmonisation of tTechnical rRequirements for Pharmaceuticals for Human uUse (ICH)","year":"2022"},{"key":"10.1016\/j.vaccine.2026.128394_bb0775","author":"WHO guidelines on non-clinical evaluation of vaccines, Annex 1, TRS No 927"},{"key":"10.1016\/j.vaccine.2026.128394_bb0780","author":"WHO Expert Committee on Biological Standardization 74th Report Annex 3"},{"key":"10.1016\/j.vaccine.2026.128394_bb0785","author":"FDA Considerations for quality, safety and efficacy of prophylactic lipid nanoparticle mRNA vaccines"},{"key":"10.1016\/j.vaccine.2026.128394_bb0790","author":"Office of Vaccines and Blood products, Pharmaceutical and Medical Devices Agency"},{"key":"10.1016\/j.vaccine.2026.128394_bb0795","series-title":"Molecular biology of the cell","author":"Alberts","year":"2002"},{"key":"10.1016\/j.vaccine.2026.128394_bb0800","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2020.102894","article-title":"TREX1 - apex predator of cytosolic DNA metabolism","volume":"94","author":"Simpson","year":"2020","journal-title":"DNA Repair (Amst)"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128394_bb0805","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.cell.2016.01.034","article-title":"The nuclear pore complex as a flexible and dynamic gate","volume":"164","author":"Knockenhauer","year":"2016","journal-title":"Cell"},{"issue":"4\u20136","key":"10.1016\/j.vaccine.2026.128394_bb0810","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1159\/000053993","article-title":"Plasmid DNA vaccines: investigation of integration into host cellular DNA following intramuscular injection in mice","volume":"43","author":"Ledwith","year":"2000","journal-title":"Intervirology"},{"key":"10.1016\/j.vaccine.2026.128394_bb0815","series-title":"Biodistribution of mRNA vaccines in rats: enrichment in injection site and lymph tissues and rapid clearance without tissue persistence","author":"Goody","year":"2026"},{"key":"10.1016\/j.vaccine.2026.128394_bb0820","author":"European mMedicines aAgency (EMA)"},{"key":"10.1016\/j.vaccine.2026.128394_bb0825","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1002\/jat.3130","article-title":"Non-clinical safety and biodistribution of AS03-adjuvanted inactivated pandemic influenza vaccines","volume":"35","author":"Segal","year":"2015","journal-title":"J Appl Toxicol"},{"key":"10.1016\/j.vaccine.2026.128394_bb0830","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jconrel.2024.12.044","article-title":"Biodistribution and mechanisms of action of MF59 and MF59-like adjuvants","volume":"378","author":"Zhang","year":"2025","journal-title":"J Control Release"},{"key":"10.1016\/j.vaccine.2026.128394_bb0835","series-title":"ADME translational pharmacokinetics\/pharmacodynamics of therapeutic proteins: Applications in drug discovery and development","first-page":"1","article-title":"ADME processes in vaccines and PK\/PD approaches for vaccination optimization","author":"G\u00f3mez-Mantilla","year":"2016"},{"key":"10.1016\/j.vaccine.2026.128394_bb0840","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0299215","article-title":"Peak transgene expression after intramuscular immunization of mice with adenovirus 26-based vector vaccines correlates with transgene-specific adaptive immune responses","volume":"19","author":"Marquez-Martinez","year":"2024","journal-title":"PLoS One"},{"issue":"372","key":"10.1016\/j.vaccine.2026.128394_bb0845","article-title":"Perfusion pressure determines vascular integrity and histomorphological quality following perfusion fixation of the brain","volume":"15","author":"Schwarzmaier","year":"2022","journal-title":"J Neurosci Methods"},{"key":"10.1016\/j.vaccine.2026.128394_bb0850","author":"FDA Bioanalytical Method Validation Guidance for Industry"},{"key":"10.1016\/j.vaccine.2026.128394_bb0855","article-title":"Immunological and antigenic signatures associated with chronic post-vaccination syndrome (PVS) in COVID-19 vaccinees","author":"Bhattacharjee","year":"2025","journal-title":"medRxiv (preprint)"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128394_bb0860","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2025.2494934","article-title":"Detection of S1 spike protein in CD16+ monocytes up to 245 days in SARS-CoV-2-negative post-COVID-19 vaccine syndrome (PCVS) individuals","volume":"21","author":"Patterson","year":"2025","journal-title":"Hum Vaccin Immunother"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128394_bb0865","first-page":"521","article-title":"Dinman et al programmed ribosomal frameshifting Goes beyond viruses: organisms from all three kingdoms use frameshifting to regulate gene expression, perhaps signaling a paradigm shift","volume":"1","year":"2006","journal-title":"Microbe Wash DC"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128394_bb0870","doi-asserted-by":"crossref","first-page":"6742","DOI":"10.1128\/jvi.69.11.6742-6750.1995","article-title":"Ribosomal frameshifting during translation of measles virus P protein mRNA is capable of directing synthesis of a unique protein","volume":"69","author":"Liston","year":"1995","journal-title":"J Virol"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128394_bb0875","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006957","article-title":"T-cell tolerance: central and peripheral","volume":"4","author":"Xing","year":"2012","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"7993","key":"10.1016\/j.vaccine.2026.128394_bb0880","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41586-023-06800-3","article-title":"N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting","volume":"625","author":"Mulroney","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2026.128394_bb0885","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-025-09945-5","article-title":"N-methylpseudouridine directly modulates translation dynamics","author":"Rozman","year":"2026","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128394_bb0890","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111300","article-title":"N1-methylpseudouridine found within COVID-19 mRNA vaccines produces faithful protein products","volume":"40","author":"Kim","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.vaccine.2026.128394_bb0895","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109762","article-title":"The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses","volume":"255","author":"F\u00f6hse","year":"2023","journal-title":"Clin Immunol"},{"key":"10.1016\/j.vaccine.2026.128394_bb0900","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00262-016-1853-2","article-title":"Immunoglobulin G4-positive plasma cell infiltration is associated with clinicopathologic traits and prognosis of pancreatic cancer after curative resection","volume":"65","author":"Liu","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.vaccine.2026.128394_bb0905","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1020844","article-title":"mRNA vaccines against SARS-CoV-2 induce comparably low long-term IgG fc galactosylation and sialylation levels but increasing long-term IgG4 responses compared to an adenovirus-based vaccine","volume":"13","author":"Buhre","year":"2023","journal-title":"Front Immunol"},{"issue":"79","key":"10.1016\/j.vaccine.2026.128394_bb0910","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.ade2798","article-title":"Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination","volume":"8","author":"Irrgang","year":"2023","journal-title":"Sci Immunol"},{"key":"10.1016\/j.vaccine.2026.128394_bb0915","doi-asserted-by":"crossref","DOI":"10.1007\/s40121-026-01303-w","article-title":"IgG4 neutralization and sustained Total IgG fc-effector functions following repeated SARS-CoV-2 vaccination with mRNA-1273","author":"Kaplonek","year":"2026","journal-title":"Infect Dis Ther"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128394_bb0920","article-title":"Altered IgG4 antibody response to repeated mRNA versus recombinant protein SARS-CoV-2 vaccines","volume":"88","author":"Kalkeri","year":"2024","journal-title":"J Inf Secur"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26002021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26002021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:24:12Z","timestamp":1777537452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26002021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":182,"alternative-id":["S0264410X26002021"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128394","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evidence-based assessment of safety and mechanistic questions Related to mRNA COVID-19 Vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128394","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128394"}}